Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 7, 2019

Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson’s Disease: Results from a pooled meta-analysis (P3.8-033)

David Standaert, Vardhaman Patel, Sonya Snedecor, Sandeep Thakkar, Yash J. Jalundhwala, Pavnit Kukreja, David Kratochvil, Yanjun Bao, Rajesh Pahwa
First published April 16, 2019,
David Standaert
1University of Alabama at Birmingham Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vardhaman Patel
2Pharmerit International Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonya Snedecor
2Pharmerit International Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandeep Thakkar
3Hoag Hospital Orange County Irvine CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yash J. Jalundhwala
4AbbVie Inc North Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavnit Kukreja
4AbbVie Inc North Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Kratochvil
2Pharmerit International Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanjun Bao
4AbbVie Inc North Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajesh Pahwa
5University of Kansas Medical Center Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson’s Disease: Results from a pooled meta-analysis (P3.8-033)
David Standaert, Vardhaman Patel, Sonya Snedecor, Sandeep Thakkar, Yash J. Jalundhwala, Pavnit Kukreja, David Kratochvil, Yanjun Bao, Rajesh Pahwa
Neurology Apr 2019, 92 (15 Supplement) P3.8-033;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate short-term and long-term impact of carbidopa-levodopa enteral suspension (CLES) on quality of life (QoL) and activities of daily living (ADL) in patients with advanced Parkinson’s Disease (APD).

Background: In addition to the clinical trials, there is emerging data from open label real-world observational studies on the safety and efficacy of CLES. Outcomes evaluates in these studies include motor symptoms, non-motor symptoms, QoL, ADL amongst others. A meta-analysis approach allows for pooling data across multiple studies to comprehensively evaluate the impact of drug on relevant patient-centric outcomes.

Design/Methods: Published trials and observational studies examining the efficacy of CLES were identified from EMBASE, MEDLINE, Derwent Drug File, and BIOSIS Previews up to September 7, 2017. Outcomes of interest for this analysis include: (i) QoL (PDQ-8, PDQ-39, EQ-5D VAS, EQ-5D), and ADL (UPDRS-II)The pooled mean change from baseline (CFB) with 95% confidence interval (CI) was estimated for each 3-month interval up to 24 months by a random-effects model. Heterogeneity was evaluated using I2 and Q-statistic.

Results: A total of 27 studies (4 clinical trials and 23 observational studies) evaluating a total of 1,562 patients with advanced PD were included in this analysis. All outcomes of interest showed statistically significant improvement within 1–3 months of starting CLES. Improvement in PD-related QoL was sustained up to a period of 2 years after CLES initiation [For PDQ-39: CFB10–12months = −8.6(−6.58,−10.62); CFB22–24months = −7.74(−3.07,−12.40). Improvement in ADL was sustained up to a period of 2 years after CLES initiation [For UPDRS-IIOFF: CFB10–12months = −5.36(−2.03,−8.70); CFB22–24months = −3.88(−2.42,−5.34)]. Results were robust to the exclusion of studies driving heterogeneity.

Conclusions: CLES leads to improvement in QoL and ADL measures in APD patients that are consistent across a broad range of studies and persist for up to 2 years. Future analyses will evaluate correlation with other outcomes.

Disclosure: Dr. Standaert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serina Therapeutics, Abbvie Inc., the Michael J. Fox Foundation for Parkinson Research, The International Parkinson Disease and Movement Disorder Society, The Parkinson Foundation, the National Institutes of Health, Oregon Health Sciences University, Voyager Therapeutics, Blue Rock Therapeutics, Clintrex LLC, Revivo Therapeutics, Sanofi-Adventis Research and Development, and US Department of Justice. Dr. Standaert has received license feed payments, royalties, or contractual rights from McGraw Hill, Inc. Dr. Standaert has received research support from Abbvie, Inc., Avid Radiopharmaceuticals, the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson Research, Alabama Department of Commerce, the Bachmann-Strauss Dystonia; Parkinson Foundation, and NIH grants. Dr. Patel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pharmerit International. Dr. Patel has received research support from Pharmerit International and AbbVie. Dr. Snedecor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pharmerit International. Dr. Snedecor has received research support from AbbVie, Inc. Dr. Thakkar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received consulting fees from Abbvie. Dr. Jalundhwala has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie. Dr. Jalundhwala holds stock and/or stock options in AbbVie which sponsored research in which Dr. Jalundhwala was involved as an investigator. Dr. Kukreja has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Kukreja holds stock and/or stock options in AbbVie Inc which sponsored research in which Dr. Kukreja was involved as an investigator. Dr. Kukreja holds stock and/or stock options in AbbVie Inc. Dr. Kratochvil has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pharmerit International . Dr. Kratochvil has received research support from Pharmerit International, which has received study funding from AbbVie for conducting the Study. Dr. Bao has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie, Inc. Dr. Bao holds stock and/or stock options in AbbVie, Inc., which sponsored research in which Dr. Bao was involved as an investigator. Dr. Pahwa has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, ACADIA, Acorda, Adamas, Cynapsus, Global Kinetics, Ionis, Lundbeck, Neurocrine Biosciences, St. Jude Medical, Sunovion, Teva Neuroscience, UCB and US World Meds. Dr. Pahwa has received personal compensation in an editorial capacity for Abbvie, ACADIA, Acorda, Adamas, Cynapsus, Global Kinetics, Ionis, Lundbeck, Neurocrine Biosciences, St. Jude Medical, Sunovion, Teva Neuroscience, UCB and US World Meds. Dr. Pahwa has received research support from Abbvie, ACADIA, Acorda, Adamas, Cynapsus, Global Kinetics, Ionis, Lundbeck, Neurocrine Biosciences, St. Jude Medical, Sunovion, Teva Neuroscience, UCB and US World Meds. Received research grants from Abbott, AbbVie, Acorda, Adamas, BMS, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec, Jazz, Kyowa, Lilly, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, Pfizer, Prexton, Roche, Sunovion and US WorldMeds.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise